![]() Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Equities analysts forecast that Rocket Pharmaceuticals will post -3.08 EPS for the current year. During the same quarter in the previous year, the company earned ($0.67) earnings per share. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.11. Rocket Pharmaceuticals ( NASDAQ:RCKT – Get Rating) last announced its quarterly earnings results on Thursday, May 4th. The company has a 50-day moving average price of $20.82 and a two-hundred day moving average price of $19.94. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.62 billion, a PE ratio of -6.00 and a beta of 1.22. Rocket Pharmaceuticals has a twelve month low of $11.78 and a twelve month high of $24.53. Shares of NASDAQ:RCKT opened at $20.10 on Wednesday. Hedge funds and other institutional investors own 96.94% of the company’s stock. Wellington Management Group LLP now owns 4,107,928 shares of the biotechnology company’s stock worth $70,369,000 after buying an additional 600,911 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in Rocket Pharmaceuticals by 17.1% in the 1st quarter. State Street Corp now owns 3,392,333 shares of the biotechnology company’s stock worth $54,142,000 after purchasing an additional 856,076 shares during the last quarter. State Street Corp raised its position in shares of Rocket Pharmaceuticals by 33.8% in the 3rd quarter. now owns 1,551,774 shares of the biotechnology company’s stock worth $24,612,000 after purchasing an additional 886,919 shares during the last quarter. raised its position in shares of Rocket Pharmaceuticals by 133.4% in the 1st quarter. now owns 4,407,623 shares of the biotechnology company’s stock worth $75,503,000 after purchasing an additional 1,011,805 shares during the last quarter. raised its position in shares of Rocket Pharmaceuticals by 29.8% in the 1st quarter. Avidity Partners Management LP purchased a new position in shares of Rocket Pharmaceuticals in the 4th quarter worth about $29,885,000. Several large investors have recently modified their holdings of RCKT. Finally, William Blair reissued an “outperform” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 22nd. Chardan Capital decreased their price target on shares of Rocket Pharmaceuticals from $63.00 to $61.00 in a research note on Friday, May 5th. started coverage on shares of Rocket Pharmaceuticals in a research note on Thursday, May 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 19th. RCKT has been the topic of a number of recent analyst reports. The average 1 year price target among brokers that have covered the stock in the last year is $51.09. Twelve equities research analysts have rated the stock with a buy recommendation. ( NASDAQ:RCKT – Get Rating) has earned a consensus rating of “Buy” from the twelve analysts that are currently covering the company, MarketBeat reports. ![]() On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.Rocket Pharmaceuticals, Inc. VACQ stock was up 27.9% as of Monday morning. Vector Acquisition and Rocket Labs are expecting the SPAC merger to close in the second quarter of 2021.That comes from cash currently held by Rocket Labs, $320 million held in trust by Vector Acquisition, and $470 million from private investment in public equity (PIPE).The new company will have roughly $750 million in cash on its balance sheet.This will also see shares of VACQ stock change over to the new RKLB stock ticker.When the deal closes, the new company will operate under the name Rocket Lab USA, Inc. ![]() The Rocket Labs SPAC merger values the company at $4.1 billion.As of this writing, the company has placed 97 satellites in orbit.It works with private and public organizations to launch satellites into orbit.Rocket Labs is a company that specializes in launch and space system services.Slusky also serves as the founder and chief investment officer of Vector Capital.The company’s CEO is tech investor Alex Slusky.It has the financial support of Vector Capital.Vector Acquisition is a blank-check company created with the goal of taking a private company public via a SPAC merger.Here’s everything potential investors in VACQ stock need to know about the companies and the deal.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |